Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide.

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy. Millions of women with breast cancer could be spared chemotherapy with a groundbreaking genomic test, according to the results of a trial that could transform healthcare guidelines worldwide. Treatment for breast cancer, the world’s most prevalent form of the disease, involves surgery to remove tumours. Chemotherapy is then usually recommended when doctors believe there is a risk the disease will return. But chemotherapy’s toxic side-effects, which can include hair loss, rashes, nausea, insomnia and fatigue, are physically and emotionally gruelling for patients. Some women may face life-changing consequences such as infertility, cognitive impairment or early menopause. For decades, there has been little choice for patients. Now scientists have develop...